Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, One-sequence, Two Periods, Crossover Trial Study to Evaluate the Effect of T89 on the Pharmacokinetics of Five CYP450 Substrates Cocktail in Healthy Subjects

NCT01473888 is registered in ClinicalTrials.gov with Tasly Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01473888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01473888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, One-sequence, Two Periods, Crossover Trial Study to Evaluate the Effect of T89 on the Pharmacokinetics of Five CYP450 Substrates Cocktail in Healthy Subjects
Lead sponsor
Tasly Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2011
Completion date
January 31, 2012
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stable angina